pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ALECAlector, Inc.

$ALEC
South San Francisco, CA, USupdated 21d ago

Alector refers to more than one person in classical mythology and history:Alector, son of Magnes and Meliboea, eponyms of Magnesia and the town of Meliboea respectively. Alector, the Boeotian father of Leitus. Homer calls him "Alectryon", and Diodorus "Electryon", naming him among the sons of Itonus. According to Tzetzes, Alector was also the father of Clonius, Arcesilaus and Prothoenor by different mothers: he is said to have fathered Leitus with Polybule, Arcesilaus with Cleobule, Prothoenor with Arteis, and Clonius with Acteis. Alector, an Elean prince as the son of King Epeius, and brother

read more…

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
nivisnebart
Alzheimer's Disease

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Diseaseterminatedn=197
  • phase3A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)terminatedn=119
  • phase3Continuation Study for Latozinemabterminatedn=17
  • phase2A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)completedn=33
  • phase2A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Diseasecompletedn=356
  • phase2A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSterminatedn=5

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 16, 26SELLWong-Sarad Grace· Principal Accounting Officer1,820 sh @ $2.65−$5K↗
  • Mar 10, 26SELLWong-Sarad Grace· Principal Accounting Officer1,000 sh @ $2.65−$3K↗
  • Mar 3, 26SELLWong-Sarad Grace· Principal Accounting Officer3,367 sh @ $2.08−$7K↗
  • Mar 2, 26SELLRosenthal Arnon· Chief Executive Officer81,864 sh @ $2.12−$174K↗
  • Mar 2, 26SELLBerkley Neil Lindsay· CFO & Chief Business Officer29,649 sh @ $2.12−$63K↗
  • Mar 2, 26SELLWong-Sarad Grace· Principal Accounting Officer8,071 sh @ $2.12−$17K↗
  • Feb 26, 26SELLWong-Sarad Grace· Principal Accounting Officer4,079 sh @ $2.50−$10K↗
routine RSU / option mechanics (2)
  • Mar 15, 26grantBerkley Neil Lindsay · CFO & Chief Business Officer54,600 sh
  • Mar 13, 26grantRosenthal Arnon · Chief Executive Officer116,246 sh
🐶 Hiring Signal
No open roles indexed yet — view Alector, Inc. jobs →

News

  • GSK walks away from Alector pact as immuno-neurology bet fizzles
    After two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s e…
    endpoints · 1mo ago
  • Avalyn's upsized IPO; Alector ends another study in GSK partnership
    🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...
    endpoints · 3mo ago
identifiers
ticker
$ALEC
SEC CIK
0001653087
country
US
source
sec_tickers
top tags
Alzheimer's Disease1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 29m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?